Explore ViiV Healthcare

I am a
... looking for

Medicines in Development

ViiV Healthcare is committed to developing new medicines for HIV to reduce its impact on the more than 36 million people living with the virus.1 Our scientists and researchers continue to work to identify new ways to lessen the burden not only of the disease, but also of daily treatment of HIV.

Clinical development pipeline 

Product
Class
Phase
LA cabotegravir + LA rilpivirine*
(for intramuscular injection)
INSTI + NNRTI
III
LA cabotegravir
INSTI
III
fostemsavir
Attachment inhibitor
III
Combinectin (GSK3732394)
Entry inhibitor
Pre-clinical
GSK3640254
Maturation inhibitor
Pre-clinical

*in collaboration with Janssen

INSTI = integrase strand transfer inhibitor; LA = long-acting; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside transcriptase inhibitor; STR = single-tablet regimen

1. UNAIDS. Global HIV & AIDS Statistics — 2018 Fact Sheet. Available at: http://www.unaids.org/en/resources/fact-sheet. Last Accessed October 2018.



Website images are not intended to imply that the models pictured have HIV.